RudaCure le PDG Yongho Kim and BD membre de l'équipe Harris Hasrol participated in the University of Utah technology briefing held from September 25 to 29, where they promoted de l'entreprise technologies to U.S.-based capital-risqueists and conducted investissement meetings.
Selon their report, there was strong interest from local attendees in the chronic traitement de la douleur, ainsi que significatif attention toward the traitement de la sécheresse oculaire and récupération des lésions cornéennes agent actuellement in clinical preparation. The reception indicated an active desire to move forward with recherche conjointe and investissement opportunities.
It is expected that the investisseur presentation taking place in San Francisco from October 2nd onward will also yield positive results.
Following the San Francisco investisseur presentation, BD membre de l'équipe Harris Hasrol will travel to Singapore to attend the Shinhan Square Bridge-organized investisseur roadshow (October 10–13), where he will present de l'entreprise technologies to Asian investisseurs. He will then travel to Europe to attend Bio Europe, where he plans to discuss specific details of transfert de technologie with Ceva, with whom RudaCure is actuellement in discussions regarding développement de médicaments vétérinaires.